Retatrutide

GIP + GLP-1 + glucagon triple agonist · Eli Lilly

Top dose
12 mg
Weight loss
-28.3%
at week 80 · efficacy
AE discontinuation
11.3%
Status
phase 3

Weight loss trajectory #

Weight loss trajectory for Retatrutide 12 mg over 80 weeks in the TRIUMPH-1 trial.

Pivotal trial #

Trial
TRIUMPH-1
Indication
obesity
Duration
80 weeks
ClinicalTrials.gov
NCT05882045
Sponsor
Eli Lilly

Dose-response: weight loss vs AE-led discontinuation #

Per-arm efficacy (bars, left axis) and AE-led discontinuation (dots, right axis) from Ph 2 (Jastreboff NEJM 2023). Higher doses generally trade extra weight loss for worse tolerability.

Notes #

AE-led disc 11.3% at 12 mg (TRIUMPH-1, Lilly PR 2026-05-21) vs 4.9% placebo. Extension to 104 wks: -30.3% (BMI >=35 subset). 65% reached BMI<30.